PLUS1
4.75
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd | GLMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.05 | -1.04% | 4.75 | 4.55 | 4.8796 | 4.75 | 4.80 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.44 | 5.99 | 1.55 | 25.88% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 650 | 82,300 | $ 4.71 | $ 387,688 | 78,223 | 3.02 - 7.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:05 | formt | 100 | $ 4.75 | USD |
Galmed Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 100.48M | 21.15M | 17.60M | $ - | $ - | -0.57 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Galmed Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/21/2020 | 16:32 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 5/18/2020 | 16:32 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 5/15/2020 | 16:53 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 5/15/2020 | 16:47 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 5/14/2020 | 07:01 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 5/14/2020 | 07:00 | PR Newswire (US) | Galmed Pharmaceuticals Provides Business Update and Reports.. |
| 5/07/2020 | 08:30 | PR Newswire (US) | Galmed Pharmaceuticals to Report First Quarter 2020.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLMD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.43 | 6.20 | 4.55 | 5.27 | 109,510 | -0.68 | -12.52% |
| 1 Month | 4.34 | 6.20 | 3.93 | 5.24 | 96,516 | 0.41 | 9.45% |
| 3 Months | 4.81 | 6.20 | 3.02 | 4.29 | 91,634 | -0.06 | -1.25% |
| 6 Months | 4.45 | 7.38 | 3.02 | 5.29 | 108,588 | 0.30 | 6.74% |
| 1 Year | 6.36 | 7.70 | 3.02 | 5.20 | 88,794 | -1.61 | -25.31% |
| 3 Years | 5.09 | 27.06 | 3.02 | 11.14 | 147,498 | -0.34 | -6.68% |
| 5 Years | 10.417 | 27.06 | 2.78 | 10.29 | 104,733 | -5.67 | -54.4% |
Galmed Pharmaceuticals Description
| Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |
